In oral RA treatments, INCB28050 will be following in the footsteps of Pfizer JAK inhibitor, tofacitinib, which met all primary endpoints in five pivotal trials and may be approved as early as 2012. Both drugs have very clean safety profiles and in fact have some similar safety issues including anemia and lipid increases. Approval of the Pfizer drug will bode well for Incyte. Analysts foresee a multi-billion dollar product for Pfizer (PFE).